RxDoctor Payments Data

Virginia Waymouth

Nurse Practitioner · Asheville, NCNPI 1285994798

Payments from drug & device makers

$1,996in general payments, 2019–2025

Across 63 payments — averaging $31.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$622
  • Johnson & Johnson$291
  • Pfizer$190
  • Sanofi$142
  • Takeda Pharmaceuticals U.S.A., Inc.$140
  • E.r. Squibb & Sons, L.L.C.$121
  • plus $489 from 7 others

What the payments were for

  • Food & beverage$1,92797%
  • Education$693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,996 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,525
Medicare patients
205
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$411,442
LinzessLinaclotide41$34,061
Mesalamine18$7,503
TrulancePlecanatide13$7,068
Dexlansoprazole DrDexlansoprazole19$5,514
Ursodiol22$2,533
Budesonide EcBudesonide11$2,451
Colestipol Hcl27$1,475
Famotidine115$1,471
Omeprazole104$1,391
Budesonide DrBudesonide14$1,242
Lubiprostone14$1,197
Pantoprazole Sodium56$793
Rabeprazole Sodium12$593
Esomeprazole Magnesium18$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$291$411,44215 claims
AbbVieLinzess$622$34,06141 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$115$7,06813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →